XML 58 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($)
$ in Millions
 3 Months Ended
Apr. 04, 2021
Mar. 29, 2020
Other Income and Expenses [Abstract]    
Interest income $ 0 $ (34)
Interest expense 336 390
Net interest expense 336 356
Royalty-related income (176) (119)
Net (gains)/losses on asset disposals (39) 1
Net (gains)/losses recognized during the period on equity securities [1],[2] (401) 255
Income from collaborations, out-licensing arrangements and sales of compound/product rights [3] (231) (115)
Net periodic benefit costs/(credits) other than service costs [4] (266) (103)
Certain legal matters, net 51 9
Consumer Healthcare JV equity method (income)/loss [5] (62) 33
Other, net (216) (126)
Other (income)/deductions––net $ (1,004) $ 190
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The gains in the first quarter of 2021 include, among other things, unrealized gains of $409 million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene.
[3] The first quarter of 2021 includes, among other things, $188 million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.
[4] Amounts include the impact of a change in accounting principle. See Notes 1C and 10.
[5] See Note 2B.